Alternative medicine use in blood cancer patients in France
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how patients with blood cancers use complementary and alternative therapies like herbal remedies, acupuncture, or meditation during their hospital treatment. It aims to understand what patients try and why, which may help doctors support them better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with acute leukemia, lymphoma, or myeloma
- You are currently in the hospital and receiving treatment
- You can read and understand French
- You are covered by health insurance
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how your immune system responds after you receive CAR-T cell therapy for multiple myeloma. The goal is to learn more about the treatment's effects and how well it works.
This study looks at blood samples from people with blood cancers to find markers that might predict how well immunotherapy will work. The goal is to help doctors choose the right treatment for each person.
This study follows adults who are being checked for a possible blood cancer, or who were recently diagnosed with a blood cancer within the last 6 months. It may help doctors understand the condition better and improve how early workups and care are organized.
This study looks at how patients with blood cancers are managed in real life when they receive CAR-T cell therapy. It helps doctors learn more about how well these treatments work outside of clinical trials.
This study collects blood and bone marrow samples from patients with blood cancers to understand why treatments stop working. It aims to improve future treatments.
This study looks for markers of cancer in your blood. It may help doctors learn more about your tumor and how to treat it.
Hear when a new Hematological Malignancies trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.